Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4M | 2M | 2M | 438K | 55K |
| Gross Profit | 3M | 2M | 877K | 150K | 11K |
| Operating Income | 81K | -715K | -1M | -10M | -448K |
| EBITDA | 302K | -3M | -1M | -10M | -2M |
| Net Income | -6M | -10M | -5M | -13M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0441
+6.91% today
1Y Change
+48.15%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regenerative Medical Technology Group Inc. (RMTG) is a Healthcare stock with listed on OTC. The stock last traded around $0.04 and up 48.1% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +70.4%, EPS growth of +44.3%, a dividend yield of 0.0%. What stands out right now is revenue +70.4%, EPS +44.3%, free cash flow +178.9% with operating margin -5.3% and ROIC 2.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RMTG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMTG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMTG Max Drawdown
-74.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMTG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$55.1K
-87.4% YoY
FY Net Income
-$5.9M
+54.2% YoY
Free Cash Flow
-$322.7K
+96.7% YoY
Revenue Growth
+70.4%
EPS Growth
+44.3%
Gross Margin
61.7%
Net Margin
-140.1%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4M | 2M | 2M | 438K | 55K |
| Gross Profit | 3M | 2M | 877K | 150K | 11K |
| Operating Income | 81K | -715K | -1M | -10M | -448K |
| EBITDA | 302K | -3M | -1M | -10M | -2M |
| Net Income | -6M | -10M | -5M | -13M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 531K | 2M | 3M | 43K |
| Total Assets | 4M | 3M | 8M | 9M | 220K |
| Total Liabilities | 31M | 25M | 20M | 16M | 7M |
| Shareholder Equity | -27M | -22M | -12M | -7M | -6M |
| Total Debt | 20M | 18M | 15M | 13M | 6M |
| Net Debt | 19M | 17M | 13M | 10M | 6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
323K
+96.7% YoY
Capital Expenditures
5
-225.0% YoY
Free Cash Flow
323K
+96.7% YoY
Key ratios
Gross Margin
61.7%
Operating Margin
-5.3%
Net Margin
-140.1%
ROE
24.6%
Debt / Equity
-0.62x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.